Drug discovery
Screen candidate molecules by simulating their interactions with target proteins directly.
Application / Healthcare
Personalized medicine, drug discovery, and protein folding.
Quantum computers can model molecules and proteins directly, instead of approximating them. That unlocks personalized medicine, faster drug candidates, and treatments tailored to individual genetics.
Pharma is already prototyping drug candidates using quantum simulations of small biomolecules.
What already happened, and what's next for quantum healthcare.
Feynman proposes quantum computers to simulate biology and chemistry.
Google/Harvard simulate hydrogen molecule H₂ on a superconducting quantum computer.
IBM + Roche partner on quantum for drug discovery.
Quantinuum + Boehringer Ingelheim publish first quantum-native drug discovery workflow.
Google Willow chip runs error-corrected molecular simulations.
First quantum-assisted drug candidate enters phase-1 clinical trial.
Routine simulation of small proteins (100–200 residues) at quantum accuracy.
Personalized cancer therapies designed against a patient's specific tumor mutations.
Quantum-designed antibiotics enter the global formulary.
Screen candidate molecules by simulating their interactions with target proteins directly.
Predict 3D structures for proteins that AlphaFold-style models still get wrong.
Model how a specific patient's genetic variants respond to a compound.
Quantum machine learning speeds up MRI reconstruction and diagnostic pattern recognition.
Who's actually building here — hardware makers, industry partners, and pure-play startups.
Willow chip demonstrated first below-threshold error correction — a milestone for chemistry.
Deep pharma partnerships (Cleveland Clinic, Moderna, Boehringer).
Trapped-ion hardware paired with the InQuanto drug-discovery software stack.
Betting on photonic FTQC scale as the shortest path to real biology.
First big pharma to publicly partner on quantum drug discovery (with Cambridge Quantum).
Working with IBM on quantum + generative AI for mRNA design.
Ecosystem highlights
First useful advantage: 3–7 years for narrow molecular simulation.